盟科药业：上半年亏损1.39亿元

Core Insights - The company, Amgen Pharmaceutical (688373), reported a revenue of 66.97 million yuan for the first half of 2025, reflecting a year-on-year growth of 10.26% [1] - The net profit attributable to shareholders was a loss of 139 million yuan, an improvement from a loss of 201 million yuan in the same period last year [1] - The basic earnings per share were -0.21 yuan [1] Revenue Analysis - The increase in revenue was primarily driven by the sales growth of the self-developed product, Contizolam Tablets [1] Profitability Insights - The narrowing of the net loss compared to the previous year was mainly due to a reduction in selling expenses and research and development investments [1]